NASDAQ
12.10USD
0.00 (0.00%)
We have scored 3 news catalysts on MediWound Ltd. (MDWD) over the past 12 months. The biggest single-day move next to one of them came Apr 2, 2026, when MDWD closed +3.8%: “MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in forward growth expectations and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
156.2M
P/E
—
EPS
—
Beta
0.14
52W range
11.84-19.7
Day range
12.01–12.47
Open
12.06
Prev close
12.10
Volume
155.3K
Avg volume
87K
Dividend
0.00
IPO
2014-03-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MediWound Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MDWD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
